A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Starting soon · Phase 1

Conditions studied: Dyslipidemia, Hypertension

In brief

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Key facts

Study ID

NCT07590167

Run by

Addpharma Inc.

People needed

60

Starts

2026-06-01

Expected to finish

2026-07-01

Last updated by the study team

2026-05-15

Who can join

Age: 19 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
• The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit

You may not qualify if…

• Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
• Other exclusions applied

Where it is running

• H Plus Yangji Hospita — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.